Ocular Therapeutix (OCUL) Change in Accured Expenses (2013 - 2026)

Ocular Therapeutix's Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$8.4 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 64.06% year-over-year to -$8.4 million; the TTM figure through Mar 2026 stood at $2.0 million (down 84.41% YoY), while the FY2025 annual figure was $5.2 million, up 44.26% from the prior year.
• Change in Accured Expenses was -$8.4 million for Q1 2026 at Ocular Therapeutix, down from $2.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.9 million in Q2 2024 to a low of -$14.0 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $168352.9 across 5 years, with a median of $1.9 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 930.32% in 2022, then sank 433.9% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $1.9 million in 2022, then plunged by 164.33% to -$1.2 million in 2023, then jumped by 437.56% to $4.2 million in 2024, then sank by 48.26% to $2.2 million in 2025, then slumped by 487.91% to -$8.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$8.4 million (Q1 2026), $2.2 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.